Pathways to change: Use trajectories following @entity130 -informed treatment of @entity1 with co-occurring XXXX and substance use disorders.

@entity1 @entity167 @entity1005 @entity734 @entity130
INTRODUCTION AND AIMS: Despite advances towards integration of care for @entity1 with co-occurring @entity734 ( @entity734 ) and @entity1005 ( @entity1005 ), low abstinence rates following @entity734 / @entity1005 treatment remain the norm. The utility of investigating distinct substance use trajectories is a critical innovation in the detection and refining of effective interventions for this clinical population. DESIGN AND METHODS: The present study reanalysed data from the largest randomised clinical trial to date for co-occurring @entity734 and @entity1005 in @entity1 (National Drug Abuse Treatment Clinical Trials Network; @entity1 and @entity130 Study). Randomised @entity1 (n   =   353) received one of two interventions in addition to treatment as usual for @entity734 : (i) @entity130 -informed integrative treatment for @entity1005 / @entity734 ; or (ii) an active control psychoeducation course on @entity1 's health. The present study utilised latent growth mixture models (LGMM) with multiple groups to estimate @entity1 's substance use patterns during the 12-month follow-up period. RESULTS: Findings provided support for three different trajectories of substance use in the post-treatment year: (i) consistently low likelihood and use frequency; (ii) consistently high likelihood and use frequency; and (iii) high likelihood and moderate use frequency. Covariate analyses revealed improvement in @entity1005 severity was associated with membership in a specific substance use trajectory, although receiving @entity130 -informed treatment was not. Additionally, @entity734 severity, age and after-care efforts were shown to be related to trajectory membership. DISCUSSION AND CONCLUSIONS: Findings highlight the necessity of accounting for heterogeneity in post-treatment substance use, relevance of @entity130 -informed care in @entity734 recovery and benefits of incorporating methodologies like LGMM when evaluating @entity734 treatment outcomes. [L  pez-Castro T, Hu M-C, Papini S, Ruglass LM, Hien DA. Pathways to change: Use trajectories following @entity130 -informed treatment of @entity1 with co-occurring @entity1005 and substance use disorders. Drug @entity167 Rev 2015].
